Neurogene Inc (NASDAQ:NGNE) — Market Cap & Net Worth
Market Cap & Net Worth: Neurogene Inc (NGNE)
Neurogene Inc (NASDAQ:NGNE) has a market capitalization of $418.59 Million ($418.59 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13321 globally and #3174 in its home market, demonstrating a 6.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurogene Inc's stock price $30.79 by its total outstanding shares 15801901 (15.80 Million). Review total liabilities of Neurogene Inc to assess the company's total debt and financial obligations.
Neurogene Inc Market Cap History: 2015 to 2026
Neurogene Inc's market capitalization history from 2015 to 2026. Data shows change from $3.94 Billion to $486.54 Million (-19.49% CAGR).
Index Memberships
Neurogene Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.02% | #350 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1279 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.02% | #192 of 263 |
Weight: Neurogene Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neurogene Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neurogene Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
390.52x
Neurogene Inc's market cap is 390.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $682.64 Million | $25.00 Million | -$31.59 Million | 27.31x | N/A |
| 2024 | $361.23 Million | $925.00K | -$75.14 Million | 390.52x | N/A |
Competitor Companies of NGNE by Market Capitalization
Companies near Neurogene Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Neurogene Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Neurogene Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Neurogene Inc's market cap moved from $3.94 Billion to $ 486.54 Million, with a yearly change of -19.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $486.54 Million | +49.47% |
| 2025 | $325.52 Million | -9.89% |
| 2024 | $361.23 Million | +17.96% |
| 2023 | $306.24 Million | +90.37% |
| 2022 | $160.86 Million | -89.44% |
| 2021 | $1.52 Billion | -65.82% |
| 2020 | $4.46 Billion | +14.45% |
| 2019 | $3.89 Billion | +470.37% |
| 2018 | $682.64 Million | -81.63% |
| 2017 | $3.72 Billion | -28.77% |
| 2016 | $5.22 Billion | +32.29% |
| 2015 | $3.94 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Neurogene Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $418.59 Million USD |
| MoneyControl | $418.59 Million USD |
| MarketWatch | $418.59 Million USD |
| marketcap.company | $418.59 Million USD |
| Reuters | $418.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more